医療系ベンチャー・トータルサポートオフィス：MEDISO ( Medical Innovation Support Office )

What is MEDISO

MEDISO provides support for business ventures, academia,
and individuals intending to put into practical use medicines,
medical devices, and regenerative medicinal products.
Click here for further details.

About the Medical Innovation Support Office

The medical innovation support office matches medical venture companies and academic institutions facing challenges in the practical application of medical products and devices for specialists* who provide detailed consultation and support for solving problems at each stage from research and development to practical use, as well as insurance coverage at clinical sites, while looking ahead to the overall comprehensive advances and dissemination into the global market.
* Specialists in each field provide support for the response to laws and regulations, marketing, business planning, fund rasing, management strategy, intellectual property management, and international development, etc.

This website is operated by Mitsubishi Research Institute, Inc., as a trustee under instructions from the Economic Affairs Division, Health Policy Bureau, and Ministry of Health, Labour and Welfare as a part of the total support for the medical ventures program sponsored by the Ministry of Health, Labour and Welfare.

Support targets

Ventures, academic institutions, and individuals aiming to put into practical use the medicines, medical devices, regenerative medicinal products, and novel drug-discovery technologies or medical materials subject to the Pharmaceuticals and Medical Devices Law.

Details of support

MEDISO provides support for the practical application of medicines, medical devices, regenerative medicinal products, and other products subject to the Pharmaceuticals and Medical Devices Law.
That support includes business planning, financing, advice on laws and regulations, and other assistance as required.

●Support method：We provide support via online meeting or e-mail.
●Support source：Support is provided in cooperation with experts in R&D, consultants in pharmaceutical affairs, and experts from related organizations including the Ministry of Health, Labour and Welfare.
●Remarks：Consultation and support services are free of charge.

Click here for inquiries

In case the link does not work, please contact us at the email address below
mediso@ml.mri.co.jp

Specialists Introduction

We will introduce registered specialists
(updated as necessary).

Akiyo Inoko Hewett

Inoko Law and Consulting, LLC　Principal Attorney

Main specialty areas

medicines
medical devices
regenerative medicine products

Specialized support fields

Regulatory compliance
Business planning
Funding
Business operation systems
Specialized support fields

Akiyo is an international attorney licensed in both Japan and the United States. She has extensive experience advising Japanese companies on U.S. legal matters. She began her legal career at an Am Law 200 U.S. law firm, where she advised Japanese companies of all sizes and their U.S. subsidiaries on a broad range of legal matters, including corporate governance, commercial contracts, mergers and acquisitions, and compliance. She later joined AI Medical Service Inc., a Japanese healthcare startup, where she supported global commercial agreements, regulatory compliance, and the company's U.S. operations. As a Fractional General Counsel, she now advises multiple Japanese healthcare startups on U.S. market entry, business expansion, regulatory compliance, and day-to-day legal and operational matters.

Taku Seriu

Seriu Medical Consulting Ltd. CEO
APCER Life Sciences. Senior Advisor to the Board
The Institute of Drug Development Career Promotion. Representative Director

Main specialty areas

medicines
regenerative medicine products

Specialized support fields

Regulatory compliance
Business planning
Business operation systems
Etc

A physician and Doctor of Medical Science, he began his career as an internist before leading clinical leukemia research at the Universities of Ulm and Heidelberg in Germany. After returning to Japan, he took on leadership roles including Head of Clinical Development at Nihon Schering, Executive Officer at Bristol-Myers Squibb, and Executive Vice President and Board Member at Otsuka Pharmaceutical, where he oversaw drug development, medical affairs, regulatory affairs, pharmacovigilance, and quality assurance.
He has led the development, approval, and post-marketing activities of more than 50 therapeutics and diagnostics across oncology, neuroscience, cardiovascular and renal diseases, infectious diseases, and rare diseases, contributing to global launches and appropriate-use initiatives.
He currently serves as President of Seriu Medical Consulting and Senior Advisor at APCER Life Sciences, supporting R&D strategy, safety and risk management, organizational development, and new business planning. He also advises startups on development strategy, TPP creation, and fundraising pitch preparation, and has a strong track record in post-acquisition organizational integration, aligning cultures, talent, and processes. He teaches pharmaceutical medicine at several universities and is an editor and contributing author of Introduction to Pharmaceutical Medicine, the first textbook of its kind published in Japan. He continues to practice clinical medicine and remains committed to supporting those driving pharmaceutical innovation in Japan, guided by the principle: “Learn Together, Grow Together.”

Daisuke Sugiyama

Hiroshima University, Translational Research Center, Professor

Main specialty areas

medicines
medical devices
regenerative medicine products

Specialized support fields

Regulatory compliance
Funding
Business operation systems
Specialized support fields
Etc

He obtained his PhD thesis at University of Tokyo. After working at several hospitals as a clinician, he has engaged in medical reserach at University Paris 6 (French Government Scholar), Dartmouth College (JSPS research fellow), Kyushu University and Hiroshima University. Based on the experiences working at ARO research core hospital and starting up bio-venture company, he supports and conducts both translational and clinical researches.

Moto Dohi

cdmo.jp Representative

Main specialty areas

medicines
regenerative medicine products

Specialized support fields

Business planning
Business operation systems
Etc

Moto Dohi studied biology and regenerative medicine in the United States before joining Pfizer, where he worked in formulation development, manufacturing process development, and new product launches. He subsequently spent approximately ten years in Switzerland, one of the world’s major pharmaceutical and life science hubs, working across pharmaceutical and CDMO organizations. His experience includes the development of an oncology drug-delivery product, technology transfer, clinical supply, and the resolution of manufacturing and quality challenges. He later earned an MBA from IMD Business School in Switzerland and expanded his responsibilities into finance, corporate transformation, and international business management within the pharmaceutical industry. Today, he leads cdmo.jp as its Representative and CDMO Navigator, connecting pharmaceutical companies and biotech startups with CDMOs in Japan and overseas. His main areas of support include CMC and manufacturing strategy, CDMO selection, technology transfer, GMP and quality, business development and licensing, and international expansion. Drawing on experience across both technical and management functions, as well as Japan and overseas markets, he supports entrepreneurs and researchers in developing practical pathways from promising science to development, manufacturing, and ultimately patient access. He also serves as a reservist in Japan’s Self-Defense Forces.

Motohiro Kobayashi

University of Yamanashi Hospital, Clinical Trial Management Office, Associate Professor

Main specialty areas

medicines
regenerative medicine products

Specialized support fields

Regulatory compliance
Business planning
Business operation systems

With over 30 years of practical experience in pharmaceutical companies, ranging from basic research to clinical development, licensing activities, and regulatory audits. Subsequently, I served as a technical expert in the Innovation Commercialization Support & Strategic Consultation Division of the Pharmaceuticals and Medical Devices Agency (PMDA), dealing with regulatory consultation services for academia and venture companies (especially for regenerative medicine products and pharmaceuticals). Currently, I am working in the clinical research support department of a university, supporting physician-led clinical trials and clinical research. I have experienced numerous pre-meetings and face-to-face advice with PMDA. I also have experience in application support for public research and development projects (such as Seeds C, etc.) by the Japan Agency for Medical Research and Development (AMED). In particular, I can provide detailed support for the development of regenerative medicine products (including quality and non-clinical).

About details of specialists

Introduction of measures implemented by public institutions

We will describe the measures from public institutions for pharmaceutical companies,
medical device companies, companies manufacturing regenerative medicinal products, and venture companies.

See more about measures implemented by public institutions